About This Guide

This guide provides a detailed overview of the principles behind the Digoxin Immune Fab Dose Calculator. It explains the formulas used, the data required for an accurate calculation, and key clinical considerations for administering this antidote in cases of digoxin or digitoxin toxicity. Use this information to better understand the calculator's outputs and for educational purposes.

Outputs Explained

The calculator provides a recommended dose of Digoxin Immune Fab in terms of the number of vials required. Each vial (e.g., DigiFab®) contains approximately 40 mg of digoxin-specific antibody fragments and is designed to bind approximately 0.5 mg of digoxin.

• Amount Ingested (Acute): For acute overdose, the output is based on the total milligrams of digoxin ingested. The calculation assumes an 80% bioavailability for oral digoxin tablets.
• Serum Level (Chronic): For chronic toxicity, the output is based on the patient's weight and a steady-state serum digoxin concentration. The calculator converts units to kg and ng/mL for standardization.
• Empiric (Emergency): In life-threatening situations where the ingested amount or serum level is unknown, the tool provides standard weight-based empiric dosing recommendations for adults and children.

How to Use the Calculator

Follow these steps to determine the appropriate dose:

1. Select Calculation Mode: Choose the mode that matches the clinical scenario.
   • Use "Amount Ingested" for known acute overdoses.
   • Use "Serum Level" for chronic toxicity with a known steady-state level (drawn ≥6-8 hours after the last dose).
   • Use "Empiric" for emergencies without quantitative data.
2. Enter Patient Data: Input the required values, such as the amount of digoxin ingested (in mg) or the patient's weight and serum digoxin level (with correct units).
3. Review the Results: The calculator will display the recommended dose in vials, which should be rounded up to the nearest whole vial. The output will also show the total milligram equivalent and the formula used.

Dosing Overview

The dosing of Digoxin Immune Fab is based on the total body load of digoxin. The goal is to provide enough Fab fragments to bind with the amount of digoxin in the body.

Formulas Used:

• Based on Ingestion:
  Dose (vials) = (Amount Ingested [mg] × 0.8) / 0.5 mg per vial
• Based on Serum Level:
  Dose (vials) = (Serum Level [ng/mL] × Weight [kg]) / 100

All calculated fractional vials must be rounded up to the next full vial. For administration, each vial is typically reconstituted with 4 mL of Sterile Water for Injection and infused intravenously over 30 minutes. In cases of cardiac arrest, it may be given as a rapid IV bolus.

Switching and Concomitant Therapies

Digoxin Immune Fab is an antidote, not a maintenance medication. The concept of "switching" therapies does not apply. After administration, clinicians should manage the underlying conditions and discontinue digoxin. Standard supportive care for arrhythmias, hyperkalemia, and other complications of digoxin toxicity should be continued as clinically indicated. Be aware that Digoxin Immune Fab will interfere with total digoxin immunoassays, leading to falsely high readings.

Missed Dose Information

As a single-course treatment for toxicity, the concept of a "missed dose" is not applicable. However, an inadequate clinical response or the recurrence of toxic signs (rebound toxicity) may indicate the need for an additional dose. Re-dosing should be guided by clinical judgment, considering the patient's response to the initial dose and subsequent clinical status. Rebound toxicity can occur as the Fab-digoxin complex dissociates, particularly in patients with renal failure.

Safety Alerts

• Hypersensitivity: Patients with allergies to sheep proteins or papain may be at higher risk for hypersensitivity reactions, including anaphylaxis. Pre-treatment is not routinely recommended, but resuscitation equipment should be available.
• Electrolyte Monitoring: Successful treatment will lower serum potassium levels. Monitor potassium closely, especially in patients who were hyperkalemic, to avoid treatment-induced hypokalemia.
• Congestive Heart Failure: In patients who rely on the inotropic effects of digoxin, its reversal can lead to an exacerbation of heart failure.

Frequently Asked Questions (FAQ)

1. How does the calculator round the final dose?

The calculator determines the number of vials and always rounds the result up to the nearest whole number (e.g., 6.2 vials becomes 7 vials) to ensure an adequate neutralizing dose is administered.

2. What bioavailability is assumed for ingested digoxin?

The "Amount Ingested" calculation assumes an oral bioavailability of 80% for digoxin tablets, a standard value used in this context.

3. Why is a steady-state serum level important?

For chronic toxicity, a post-distribution level (drawn at least 6-8 hours after the last dose) is crucial because it reflects the amount of digoxin distributed in the body's tissues, not just the blood. An early, high level can lead to significant dose overestimation.

4. Does the calculator work for digitoxin toxicity?

Yes, the dosing formulas apply to digitoxin as well. However, because digitoxin has a much longer half-life, the clinical effects of toxicity and the Fab-digitoxin complex clearance will be more prolonged.

5. How is the dose adjusted for patients with renal failure?

No initial dose adjustment is required. However, the inactive Fab-digoxin complex is cleared by the kidneys, so its elimination will be delayed in patients with renal impairment, increasing the risk of rebound toxicity.

6. What should I do if the patient's weight or ingested amount is unknown?

In a life-threatening emergency where quantitative data is unavailable, you should use the "Empiric" mode, which provides standard dosing recommendations (e.g., 10-20 vials for an adult).

7. How much digoxin does one 40 mg vial neutralize?

Each 40 mg vial of Digoxin Immune Fab binds approximately 0.5 mg of digoxin.

8. What are the signs of a successful response to treatment?

A positive response includes resolution of life-threatening arrhythmias (e.g., ventricular tachycardia, severe bradycardia) and normalization of hyperkalemia.

9. When should I consider giving a repeat dose?

A second dose may be considered if the initial response is inadequate or if signs of toxicity reappear after initial improvement. This decision should be based on ongoing clinical assessment.

10. Can I give Digoxin Immune Fab as a rapid push?

Yes, in situations of imminent cardiac arrest, the dose may be administered as an intravenous bolus (push) rather than the standard 30-minute infusion.

References

• DigiFab® (digoxin immune Fab [ovine]) Prescribing Information. U.S. Food and Drug Administration. Accessed October 2023.
• Bayer, M. J. (2023). Digitalis (cardiac glycoside) poisoning. In T.W. Post (Ed.), UpToDate. Accessed October 2023.
• Antman, E. M., Wenger, T. L., Butler, V. P., Haber, E., & Smith, T. W. (1990). Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. Circulation, 81(6), 1744–1752.
• National Capital Poison Center. Digoxin. Accessed October 2023.